CA2383626A1 - Traitement de tumeurs cutanees, verrues et infections virales utilisant du p. acnes tue par la chaleur - Google Patents

Traitement de tumeurs cutanees, verrues et infections virales utilisant du p. acnes tue par la chaleur Download PDF

Info

Publication number
CA2383626A1
CA2383626A1 CA002383626A CA2383626A CA2383626A1 CA 2383626 A1 CA2383626 A1 CA 2383626A1 CA 002383626 A CA002383626 A CA 002383626A CA 2383626 A CA2383626 A CA 2383626A CA 2383626 A1 CA2383626 A1 CA 2383626A1
Authority
CA
Canada
Prior art keywords
acnes
bacterial product
warts
product
propionibacterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002383626A
Other languages
English (en)
Inventor
Bobby G. Edwards
Kent R. Van Kampen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Van Kampen Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Van Kampen Group Inc filed Critical Van Kampen Group Inc
Publication of CA2383626A1 publication Critical patent/CA2383626A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des suspensions salines de Propionibacterum acnes, Propionibacterium avidum, Propionibacterium lymphophylum, Propionibacterium granulosum, Cornyebacterium parvum, et Arachnia propionica stérilisées et tuées à la chaleur efficaces dans le traitement d'infections virales des voies respiratoires de l'homme et dans la promotion de la régression des tumeurs cutanées, verrues chez l'homme. L'activité thérapeutique de cette suspension saline de Propionibacterium acnes (P. acnes) a été démontrée par un modèle d'animal de laboratoire. Le produit P. acnes est administré par voie orale à des fins de prévention ou de traitement des infections virales des voies respiratoires chez l'homme. La préparation P. acnes est administrée par voie intralésionnelle dans les tumeurs cutanées et les verrues, notamment les verrues plantaires ou d'autres verrues provoquées par le papillomavirus afin de faire régresser les tumeurs cutanées et les verrues. L'administration par voie sous-cutanée duP. acnes entraîne une réaction systémique qui se traduit par la disparition totale des verrues sur le long terme. Des anesthésiques comme Lidocaïne peuvent être ajoutés au produit à base de P. acnes afin de prévenir la douleur lors de l'injection de cette préparation d'immunomodulation tout en maintenant l'activité thérapeutique du produit de P. acnes. Des dosages ont été établis pour l'administration par voie orale dudit produit de P. acnes afin de traiter les infections virales et pour l'administration par voie sous-cutanée et intralésionnelle du même produit afin de traiter les tumeurs cutanées et les verrues.
CA002383626A 1999-10-15 2000-10-13 Traitement de tumeurs cutanees, verrues et infections virales utilisant du p. acnes tue par la chaleur Abandoned CA2383626A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15956799P 1999-10-15 1999-10-15
US60/159,567 1999-10-15
PCT/US2000/028361 WO2001054727A1 (fr) 1999-10-15 2000-10-13 Traitement de tumeurs cutanees, verrues et infections virales utilisant du p. acnes tue par la chaleur

Publications (1)

Publication Number Publication Date
CA2383626A1 true CA2383626A1 (fr) 2001-08-02

Family

ID=22573102

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002383626A Abandoned CA2383626A1 (fr) 1999-10-15 2000-10-13 Traitement de tumeurs cutanees, verrues et infections virales utilisant du p. acnes tue par la chaleur

Country Status (5)

Country Link
EP (1) EP1220688A1 (fr)
AU (1) AU1201801A (fr)
CA (1) CA2383626A1 (fr)
MX (1) MXPA02003742A (fr)
WO (1) WO2001054727A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115317520A (zh) * 2022-09-06 2022-11-11 浙江大学 一种锌铝类水滑石-痤疮丙酸杆菌细菌杂化材料及其制备方法、应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2002534468A (ja) 1999-01-13 2002-10-15 バイエル コーポレイション ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
EP2324825A1 (fr) 2002-02-11 2011-05-25 Bayer Healthcare LLC Arylurées dotées d'une activité d'inhibition de l'angiogenèse
ATE366108T1 (de) 2003-05-20 2007-07-15 Bayer Pharmaceuticals Corp Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
NZ580384A (en) 2003-07-23 2011-03-31 Bayer Pharmaceuticals Corp 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
US7662781B2 (en) 2005-01-31 2010-02-16 Eci, Inc. Immunopotentiating agent
EP2455092A1 (fr) 2010-11-11 2012-05-23 Nestec S.A. Protection de micro-organismes probiotiques sans réplication contre les infections des voies respiratoires supérieures
CN117511758A (zh) * 2022-08-04 2024-02-06 复旦大学附属华山医院 痤疮丙酸杆菌、其应用、组合物和药物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4479935A (en) * 1980-04-22 1984-10-30 Institut Pasteur Fractions extracted from aerobic bacteria, endowed with antitumoral, antibacterial and interferon inducing properties, and process for their preparation
JPS59161320A (ja) * 1983-03-04 1984-09-12 Maruyama Chisato リポ多糖体およびその製造法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115317520A (zh) * 2022-09-06 2022-11-11 浙江大学 一种锌铝类水滑石-痤疮丙酸杆菌细菌杂化材料及其制备方法、应用
CN115317520B (zh) * 2022-09-06 2024-04-05 浙江大学 一种锌铝类水滑石-痤疮丙酸杆菌细菌杂化材料及其制备方法、应用

Also Published As

Publication number Publication date
AU1201801A (en) 2001-08-07
WO2001054727A1 (fr) 2001-08-02
EP1220688A1 (fr) 2002-07-10
MXPA02003742A (es) 2003-10-14

Similar Documents

Publication Publication Date Title
JPS60155123A (ja) 癌の診断・治療剤と製品、ならびに細胞及び体液性免疫防御の低能の治療剤と製品
EP0752870B1 (fr) Utilisation de mycobacterium pour le traitement des tumeurs
KR100333113B1 (ko) 헬리코박터피롤리관련위십이지장질환의치료방법
AU691797B2 (en) Immunotherapeutic composition
SHAUGHNESSY et al. Experimental human bacillary dysentery: polyvalent dysentery vaccine in its prevention
US6726913B1 (en) Treatment of dermal tumors, warts, and viral infections of the respiratory tract in humans using heat-killed P. acnes
JP5101795B2 (ja) 免疫モジュレーターとしての全細菌細胞
CA2383626A1 (fr) Traitement de tumeurs cutanees, verrues et infections virales utilisant du p. acnes tue par la chaleur
US4938956A (en) Synergistic immunostimulating composition and method
UA79952C2 (en) MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
JPH02503800A (ja) 炎症過程及びアレルギー性疾患の予防及び治療のための細菌性製剤
US20090226490A1 (en) Use of Whole Bacterial Cells (Actinomycetales) for Maternal Administration to Modulate Offspring Immune Response
TWI245636B (en) gamma delta T cell immunoactivity enhancers containing extract of Lentinus edodes mycelium
JP3040711B2 (ja) 抗腫瘍剤及びその製造法
RU2129867C1 (ru) Средство для профилактики и лечения инфекционных заболеваний и коррекции патологических состояний живого организма
CN113827604B (zh) 瑞德西韦在制备治疗肿瘤或抗肿瘤转移药物中的应用
RU2681546C1 (ru) Способ экстренной профилактики клещевого вирусного энцефалита
Mahe et al. Therapeutic trial with reticulostimulin in patients with ear, nose, or throat cancers
JPH03109331A (ja) 腫瘍壊死因子効果増強剤
JP2024064835A (ja) 狂犬病暴露後治療剤
EP4157348A1 (fr) Compositions et méthodes permettant de traiter une dépendance à la morphine, à l'héroïne et à l'alcool
RU2230505C2 (ru) Способ профилактики туберкулеза крупного рогатого скота
RU2292916C1 (ru) Способ иммунопрофилактики острых респираторных болезней телят
RU2371187C1 (ru) Способ лечения паралича и эпилепсии у собак
MAHÉ et al. M. BRUNET, G. HALPERN, B. DEBAUD, and F. ROTH

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead